Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial
Sudhan, Dhivya R., Schwarz, Luis J, GUERRERO-ZOTANO, ANGEL, Formisano, Luigi, Nixon, Mellissa J, Croessmann, Sarah, Gonzalez-Ericsson, Paula I, Sanders, Melinda, Balko, Justin M, Avogadri-Connors, FraLanguage:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-18-1131
Date:
October, 2018
File:
PDF, 3.91 MB
english, 2018